A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT02439450

Public ClinicalTrials.gov record NCT02439450. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will test whether vaccination with viagenpumatucel-L combined with strategies to modulate the immune response is safe for patients with non-small cell lung adenocarcinoma or squamous cell carcinoma for incurable or metastatic disease.

Study identification

NCT ID: NCT02439450
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Heat Biologics; Industry
Enrollment: 121 participants

Conditions and interventions

Conditions

Non-small Cell Lung Cancer

Interventions

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 15, 2015 (Actual)
Primary completion: May 3, 2021 (Actual)
Completion: Nov 4, 2022 (Actual)
Last update posted: Sep 21, 2023

2015 – 2022

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
University of Arizona Cancer Center	Tucson	Arizona	85724	—
UC San Diego	La Jolla	California	92093	—
BRRH Lynn Cancer Institute	Boca Raton	Florida	33486	—
Memorial Cancer Institute	Pembroke Pines	Florida	33028	—
Horizon Oncology Research	Lafayette	Indiana	47905	—
Ashland-Bellefonte Cancer Center	Ashland	Kentucky	41101	—
Baptist Health Louisville	Louisville	Kentucky	40207	—
Washington University School of Medicine	St Louis	Missouri	63110	—
New York Oncology Hematology	Albany	New York	12206	—
Winthrop Hospital	Mineola	New York	11501	—
Oncology Hematology Care, Inc.	Cincinnati	Ohio	45242	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Providence Portland Medical Center	Portland	Oregon	97213	—
University of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Rhode Island Hospital	Providence	Rhode Island	02903	—
Virginia Cancer Specialists	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02439450, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 21, 2023 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02439450 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →